Physician

Wieslawa A. Pekal, M.D.

According to 2025 Medicare claims, Wieslawa Pekal, M.D. (NPI: 1508856436) practices hematology/oncology in the Asheville, NC market, with the plurality of this provider's patient population coming from Buncombe, NC. This provider's primary affiliated billing organization is AMERICAN ONCOLOGY PARTNERS PA (NPI: 1265929723; TIN: 824681345) and primary practice location at 28806-2316. Pekal is affiliated with the Mission Health Partners, LLC (ACO ID: A2591), participating under the MSSP model.

Pekal's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 965 traditional Medicare patients, billed 119,148 HCPCS/CPT codes, and received $1,994,406 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,373 prescription claims across 201 beneficiaries totaling $3,996,966 in drug costs, led by Revlimid (Lenalidomide). 2021 DME data shows 31 claims. Open Payments data shows 61 records totaling $1,522. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $777,984 to $1,994,406. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $603,287 to $3,996,966. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $5,854 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	776	64,944	$777,984
2016	725	78,445	$1,093,254
2017	494	59,926	$935,668
2018	275	1,697	$50,232
2019	312	770	$49,639
2020	570	62,442	$942,099
2021	760	68,564	$1,038,642
2022	847	105,411	$1,867,715
2023	1,065	147,378	$2,417,248
2024	965	119,148	$1,994,406

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	282	1,515	$603,287
2016	254	1,263	$626,205
2017	251	1,254	$872,052
2018	276	1,120	$879,485
2019	257	1,242	$1,762,040
2020	176	1,076	$2,411,392
2021	167	986	$2,633,316
2022	187	1,092	$2,687,769
2023	180	1,145	$2,896,598
2024	201	1,373	$3,996,966

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	117	$30,885
2016	N/R	69	$13,435
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	14	$902
2020	N/R	30	$1,292
2021	N/R	31	$1,397
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	129	237	$90
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	266	418	$85
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	275	469	$60
36415	Insertion of needle into vein for collection of blood sample	599	1,621	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	651	1,723	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	81	2,268	$1,418,948
Imbruvica	Ibrutinib	46	1,288	$724,460
Besremi	Ropeginterferon Alfa-2b-Njft	18	504	$279,847
Sprycel	Dasatinib	17	510	$262,642
Bosulif	Bosutinib	11	330	$162,242

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	61	$1,522	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Wieslawa A. Pekal, M.D.?

Tedicare shows public-source Medicare data for Wieslawa A. Pekal, M.D. (NPI 1508856436), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Wieslawa A. Pekal, M.D. have ACO affiliation data?

Wieslawa A. Pekal, M.D. is shown with ACO affiliation data for Mission Health Partners, LLC (MSSP, ACO ID A2591).

What billing organization is linked to Wieslawa A. Pekal, M.D.?

Wieslawa A. Pekal, M.D. is linked to AMERICAN ONCOLOGY PARTNERS PA (billing NPI 1265929723) in the available physician profile data.

Does Wieslawa A. Pekal, M.D. have Open Payments data?

Wieslawa A. Pekal, M.D. has 61 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.